Background: A recent randomized phase III study of 719 de novo liver transplant recipients showed that early everolimus plus reduced-dose tacrolimus (EVR + rTAC) led to significantly better kidney function than standard TAC (TAC-C), without compromising efficacy. In that study, patients from North America (n = 211) had increased risk factors for posttransplant renal insufficiency at study start, relative to patients from Europe and rest of world (eg, worse renal function, more diabetes, older age).
Methods: A post hoc analysis was performed to assess whether these regional disparities affected study outcomes in North American patients.
Results: In this subpopulation, estimated glomerular filtration rates at randomization were higher in TAC-C over EVR + rTAC (76.4 vs 69.3 mL/min per 1.73 m). Mean changes in estimated glomerular filtration rate values (mL/min per 1.73 m) favored EVR + rTAC over TAC-C at months 12 (+3.7 vs -4.5; P = 0.032), 24 (+2.7 vs -6.6; P = 0.042), and 36 (+4.3 vs -8.1; P = 0.059). The composite efficacy endpoint of treated biopsy-proven acute rejection, graft loss, or death was 10.9%, 14.1%, and 14.1% for EVR + rTAC and 13.1%, 17.2%, and 19.3% for TAC-C at months 12, 24, and 36, respectively.
Conclusions: Although the North American cohort had more comorbidities, results were consistent with the overall population for efficacy and renal function.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265688 | PMC |
| http://dx.doi.org/10.1097/TP.0000000000001524 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma.
Ann Transplant
November 2022
Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan.
BACKGROUND The study objective was to evaluate the effect of everolimus (EVR) in combination with reduced tacrolimus (rTAC) compared with a standard TAC (sTAC) regimen on hepatocellular carcinoma (HCC) recurrence in de novo living-donor liver transplantation recipients (LDLTRs) with primary HCC at liver transplantation through 5 years after transplantation. MATERIAL AND METHODS In this multicenter, non-interventional study, LDLTRs with primary HCC, who were previously randomized to either everolimus plus reduced tacrolimus (EVR+rTAC) or standard tacrolimus (sTAC), and who completed the 2-year core H2307 study, were followed up. Data were collected retrospectively (end of core to the start of follow-up study), and prospectively (during the 3-year follow-up study).
View Article and Find Full Text PDFBackground And Aim: reduction in calcineurin inhibitor levels is considered crucial to decrease the incidence of kidney dysfunction in liver transplant (LT) recipients. The aim of this study was to evaluate the safety and impact of everolimus plus reduced tacrolimus (EVR + rTAC) vs. mycophenolate mofetil plus tacrolimus (MMF + TAC) on kidney function in LT recipients from Spain.
View Article and Find Full Text PDFEarly Everolimus-Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial.
Liver Transpl
June 2022
Department of Hepatobiliary Surgery and Visceral Transplantation University Medical Center Hamburg-Eppendorf Hamburg Germany Department of General, Visceral and Transplant Surgery University Hospital Heidelberg Heidelberg Germany Department of General, Visceral, Thoracic, Transplant and Pediatric Surgery University Medical Center Schleswig-Holstein Kiel Germany Department of Surgery University Hospital Regensburg Regensburg Germany Department of General, Visceral and Transplant Surgery Charité-Universitätsmedizin Berlin Berlin Germany Department of General, Visceral and Transplantation Surgery University Hospital Essen Essen Germany Department of General, Visceral and Transplant Surgery University Hospital Aachen Aachen Germany Novartis Pharma GmbH Nürnberg Germany Organ Transplantation Center The First Affiliated Hospital of University of Science and Technology of ChinaAnhui Provincial Hospital Hefei China General, Visceral and Transplant SurgeryDepartment of Surgery Medical University of Graz Graz Austria Department of General, Visceral and Transplantation Surgery University Hospital Münster Münster Germany Department of GeneralVisceral and Transplant Surgery University Hospital Aachen Aachen Germany Department of General Surgery Maastricht University Medical Centre (MUMC) Maastricht the Netherlands.
Everolimus-facilitated reduced-exposure tacrolimus (EVR + rTAC) at 30 days after liver transplantation (LT) has shown advantages in renal preservation. This study evaluated the effects of early initiation of EVR + rTAC in de novo LT recipients (LTRs). In HEPHAISTOS (NCT01551212, EudraCT 2011-003118-17), a 12-month, multicenter, controlled study, LTRs were randomly assigned at 7 to 21 days after LT to receive EVR + rTAC or standard-exposure tacrolimus (sTAC) with steroids.
View Article and Find Full Text PDFBackground And Methods: Data from 2 randomized liver transplant trials (N = 772; H2304 [deceased donor, n = 488], H2307 [living donor, n = 284]) were pooled to further evaluate the efficacy and safety of everolimus with reduced tacrolimus (EVR + rTAC) versus standard tacrolimus (sTAC) regimen at month 24.
Results: EVR + rTAC was comparable to sTAC for composite efficacy failure of treated biopsy-proven acute rejection, graft loss, or death (9.8% versus 10.
Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal.
Am J Transplant
January 2021
Novartis Pharma AG, Basel, Switzerland.
CRADLE was a 36-month multicenter study in pediatric (≥1 to <18 years) kidney transplant recipients randomized at 4 to 6 weeks posttransplant to receive everolimus + reduced-exposure tacrolimus (EVR + rTAC; n = 52) with corticosteroid withdrawal at 6-month posttransplant or continue mycophenolate mofetil + standard-exposure TAC (MMF + sTAC; n = 54) with corticosteroids. The incidence of composite efficacy failure (biopsy-proven acute rejection [BPAR], graft loss, or death) at month 36 was 9.8% vs 9.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!